ULTOMIRIS (Alexion Pharmaceuticals, Inc.)
(https://ultomiris.com) 📸 Data Snapshot: May 24, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Authority is well-established through detailed JSON-LD schema on the gMG page, which identifies the manufacturer (Alexion Pharmaceuticals) and the specific drug mechanism. There are no major authority gaps; the site clearly identifies itself as an official brand property and provides professional-grade regulatory documentation.
The performance claims are bold but strictly quantified. Claiming a ‘98.6% reduced risk of relapse’ is a massive performance assertion that is immediately qualified by placebo-controlled clinical trial data. The marketing tone is secondary to the regulatory and clinical substance.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
/gmg/
{
"@context": "https://schema.org/",
"@type": "MedicalWebPage",
"url": "https://ultomiris.com/gmg",
"audience": "https://health-lifesci.schema.org/Patient",
"creator": {
"@type": "Organization",
"name": "Alexion Pharmaceuticals, Inc.",
"url": "https://alexion.com",
"logo": "https://alexion.com/~/media/Alexion_comRedesign/Images/Logos/alexion.svg",
"sameAs": "https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals"
},
"specialty": [
"https://health-lifesci.schema.org/Neurologic",
"https://health-lifesci.schema.org/Musculoskeletal"
],
"mainEntity": {
"@type": "Drug",
"name": "ULTOMIRIS",
"brand": {
"@type": "Brand",
"name": "ULTOMIRIS",
"logo": "https://ultomiris.com/gmg/-/media/ultomiris_gmg/images/logo/ultomiris-logo.svg",
"sameAs": "https://en.wikipedia.org/wiki/Ravulizumab"
},
"activeIngredient": "ravulizumab-cwvz",
"administrationRoute": "IV infusion",
"isProprietary": "True",
"isAvailableGenerically": "False",
"nonProprietaryName": "",
"relevantSpecialty": "https://health-lifesci.schema.org/Neurologic",
"manufacturer": {
"@type": "Organization",
"name": "Alexion Pharmaceuticals, Inc.",
"url": "https://alexion.com",
"logo": "https://alexion.com/~/media/Alexion_comRedesign/Images/Logos/alexion.svg",
"sameAs": "https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals"
},
"description": "Learn about ULTOMIRIS, a treatment for generalized myasthenia gravis (gMG). Please see the accompanying full Prescribing Info and Med Guide, including Boxed WARNING.",
"dosageForm": "Injection",
"drugUnit": "10 mg/mL, 100 mg/mL in a single-dose vial",
"interactingDrug": {
"@type": "Drug",
"name": ""
},
"doseSchedule": [
{
"@type": "DoseSchedule",
"doseUnit": "mg/mL",
"doseValue": "300 mg/30 mL",
"frequency": "Once every 8 weeks after an initial loading dose",
"targetPopulation": "Adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive"
},
{
"@type": "DoseSchedule",
"doseUnit": "mg/mL",
"doseValue": "300 mg/3 mL, 1,100 mg/11 mL",
"frequency": "Once every 8 weeks after an initial loading dose",
"targetPopulation": "Adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive"
},
{
"@type": "DoseSchedule",
"doseUnit": "mg/mL",
"doseValue": "1,100 mg/11 mL",
"frequency": "Once every 8 weeks after an initial loading dose",
"targetPopulation": "Adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive"
}
],
"labelDetails": [
"https://alexion.com/Documents/Ultomiris_USPI.pdf",
"ttps://ultomiris.com/Pdf/ULTOMIRIS-Med-Guide.pdf"
],
"mechanismOfAction": "ULTOMIRIS is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the membrane attack complex [MAC or C5b-9]), thus preventing MAC formation. The precise mechanism by which ravulizumab-cwvz exerts its therapeutic effect in gMG patients is unknown, but is presumed to involve reduction of terminal complement complex C5b-9 deposition at the neuromuscular junction.",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"prescribingInfo": "https://alexion.com/Documents/Ultomiris_USPI.pdf",
"breastfeedingWarning": "Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.",
"pregnancyWarning": "Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS."
},
"about": {
"@type": "MedicalCondition",
"name": "generalized myasthenia gravis",
"sameAs": "https://en.wikipedia.org/wiki/Ravulizumab",
"relevantSpecialty": [
"https://health-lifesci.schema.org/Neurologic",
"https://health-lifesci.schema.org/Musculoskeletal"
],
"alternateName": "gMG",
"associatedAnatomy": {
"@type": "AnatomicalSystem",
"name": "Central nervous system "
},
"possibleTreatment": {
"@type": "MedicalTherapy",
"name": "ULTOMIRIS"
}
}
}
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /nmosd/ | 0 | 0 |
| /gmg/ | 0 | 0 |
| /ahus/ | 0 | 0 |
This page presents a snapshot of public data from ULTOMIRIS (Alexion Pharmaceuticals, Inc.), captured on May 24, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to ULTOMIRIS (Alexion Pharmaceuticals, Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://ultomiris.com to view the most current version of its content and see directly what this company is about and what it offers.